JATT SEC filings, in plain English
Everything JATT II Acquisition has filed with the SEC that we hold — 40 filings, newest first, 38 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: Routine SEC compliance exhibit comprising a Schedule 13G/A amendment and an attached Joint Filing Agreement executed on August 14, 2026, by Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz. Per the filing text signed by Managing Partner Michael Kramarz and authorized signatory Robert Egen Atkinson, the only procedural shift is the creation of a joint filing arrangement for future Schedule 13G submissions among the four named parties. The document states that each signatory accepts independent responsibility for the timeliness and accuracy of their own reported holdings while explicitly disclaiming liability for the completeness and accuracy of the others’ information. The filing introduces no modifications to the redemption calendar, the $10.07 trust per share, the 2028-04-20 deadline, JATT II Acquisition execution milestones, or sponsor oversight protocols. Why it matters: For investors tracking redemption windows, trust value preservation, extension mechanics, merger progression, and sponsor conduct, this instrument is administratively focused and carries zero operational impact. The filing contains no assertions regarding customer concentrations, revenue recognition, total addressable markets, business strategy, technological roadmaps, commercial partnerships, active litigation, or executive appointments. Its entire operative substance is limited to allocating future 13G reporting duties among the listedholders, confirming standard SEC joint-filing compliance without altering the SPAC’s statutory framework, shareholder voting triggers, or trust distribution schedules.
What changed: A Schedule 13G beneficial ownership report filed on 2026-08-14 that identifies Balyasny Asset Management L.P., BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny as reporting persons. The filing reports no adjustments to the April 20, 2028 redemption deadline, the $10.07 per-share trust value, extension mechanisms, or acquisition progress. According to the registered document, there are no disclosed changes to shareholder voting rights, sponsor capital calls, or redemption eligibility criteria. Why it matters: As a routine compliance exhibit detailing holding entities and their principal, the report attributes passive ownership structures rather than active deal execution or governance intervention. Because the filers did not attach share counts, percentage thresholds, or stated investment purposes, the filing carries no immediate impact on investor recovery calculations or sponsor conduct reviews. Investors tracking JATT’s capitalization should await subsequent 13D amendments, definitive merger agreements, or proxy statements for concrete signals on target validation, extension voting, or trust deployment schedules.
What changed: A Schedule 13G beneficial ownership report accompanied by a Joint Filing Agreement executed by ADAR1 Capital Management, LLC and Daniel Schneeberger. The filing confirms the named parties agreed to submit a single Schedule 13G to satisfy SEC reporting requirements for beneficial ownership of JATT II Acquisition Corp. Ordinary Shares. It does not alter, extend, or affect the SPAC’s redemption calendar (2028-04-20), trust value ($10.07 per share), merger execution progress, or sponsor governance. Why it matters: The submitted text is restricted to the signed joint filing agreement cover page and lacks the mandatory Schedule 13G disclosures: aggregate share counts, exact percentages, dates of last purchase, funding sources, and investment purpose. Without those figures, investors cannot assess voting concentration, potential tender participation, or activist intent. The document’s sole operational effect is administrative compliance; complete materiality depends on the omitted primary Schedule 13G form.
What changed: Routine Schedule 13G/A compliance exhibit — an amended beneficial ownership report filed by Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl. This SEC filing is an updated statement of beneficial ownership under Section 13(d). The provided excerpt contains no share quantities, percentage holdings, transaction dates, or purpose statements. Consequently, it discloses no mechanics affecting the redemption calendar, trust per-share value, extension timelines, JATT II Acquisition deal progress, or sponsor conduct. Why it matters: Section 13G/A filings track shifting capital commitments and holding patterns among SPAC sponsors and affiliated principals. Even without disclosed figures, the amendment flags a reporting obligation update that investors monitor for signals regarding lock-up status, downstream positioning before shareholder votes, or post-merger liquidity drains. Until full page content is reviewed, the document functions strictly as a cap-table tracking instrument rather than a catalyst for redemption decisions or valuation assessments.
What changed: SEC Schedule 13G (beneficial ownership report). The filing identifies Atika Capital Management LLC and Brad Farber as the reporting persons disclosing beneficial ownership in JATT. The provided text contains no share counts, percentage thresholds, acquisition dates, or explicit statements characterizing the filing as passive or active. No data is presented regarding redemption mechanics, trust-per-share valuations, extension motions, target acquisition progression, or sponsor conduct. Why it matters: A Schedule 13G legally registers that one or more persons have crossed or maintained a greater-than-5% equity stake in a public company, establishing their formal voting rights and disclosure obligations. For a SPAC in the DEAL_ANNOUNCED phase approaching a 2028-04-20 deadline, identifying large non-sponsor blockholders helps map potential aggregate redemption exposure, proxy voting alignment on a business combination, or future governance influence, though this truncated excerpt lacks the numerical ownership data or strategic narrative required to quantify those dynamics.
What changed: A Power of Attorney exhibit filed to authorize designated corporate officers to prepare and submit ownership and control-person reporting documents to the Securities and Exchange Commission. Janus Henderson Group Ltd. appointed Kristin Mariani and Caroline Barotti as severally acting attorneys-in-fact on December 9, 2022, to execute Forms 13D, 13F, 13G, 13H, and amendments as required by U.S. and non-U.S. governmental authorities. Michelle Rosenberg, identified as General Counsel and Company Secretary, executed the instrument. The document contains no provisions altering redemption deadlines, trust account valuations, extension voting, merger progress, or sponsor conduct. No assertions regarding customers, revenues, market size, strategy, technology, partnerships, litigation, or personnel changes are attributed to any party. Why it matters: For investors tracking JATT’s transaction mechanics, this exhibit is purely administrative. It ensures Janus Henderson can timely satisfy SEC reporting obligations through designated employees, but it does not trigger shareholder redemption windows, modify trust distribution conditions, signal management shifts tied to the combination, or indicate changes in deal progress or sponsor alignment.
What changed: Quarterly Report (Form 10-Q) for the period ended June 30, 2026, filed August 12, 2026. This is the first 10-Q since the IPO (April 2026). It discloses the Business Combination Agreement signed on June 29, 2026 with Talawar Tx Inc., including a $225 million PIPE at $10/share, sponsor agreement to surrender 150,000 shares, and a minimum cash condition of $125 million. Trust account per share is $10.07, slightly above the $10.00 IPO price. The company has 24 months from IPO close (April 20, 2026) to complete the deal. No redemptions have occurred yet; the redemption mechanics are described. Why it matters: The filing confirms the target and deal structure, providing investors with key terms for evaluating the proposed business combination. The trust value per share ($10.07) offers a small cushion for redemptions. The PIPE at $10/share implies a $120 million pre-money valuation for the SPAC. The sponsor's forfeiture of 150,000 shares and other concessions indicate alignment. The 24-month deadline (April 2028) is distant, but the deal is already announced.
trust account, redeemable shares, sponsor loans outstandingnothing moved · 3 with no prior record of ours
- Trust account
- not previously extracted$60.4M
- Redeemable shares
- not previously extracted6.00M
- Sponsor loans outstanding
- $106K · unchanged
The clause …“Assets 1,829,543 Long term prepaid insurance 100,284 Cash and investments held in Trust Account 60,409,419 Total Assets $ 62,339,246 Liabilities, Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit Current”…
The clause …“200,000,000 shares authorized; 1,800,000 issued and outstanding (excluding 6,000,000 shares subject to possible redemption) 180 Additional paid-in capital — Accumulated deficit ( 604,355 ) Total Shareholders’ Deficit ( 604,175 )”…
The clause …“Company determines not to conduct an Initial Public Offering. The Company had borrowed $ 106,141 under the promissory note which was fully repaid subsequent to the closing of the Initial Public Offering on April 28, 2026. Borrowings”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Form 4 insider ownership report. Per the June 30, 2026 filing, reporting person Sidhu Someit (identified in the submission as director, Chief Executive Officer, and 10% owner of JATT II Acquisition Corp.) disposed of 225,000 shares at $0 on June 6, 2026. The filing attests he holds 1,800,000 shares post-transaction. The document records no modifications to the $10.07 trust/share balance, the April 20, 2028 deadline, or the currently announced deal status. Why it matters: This filing does not trigger redemption clock resets, alter trust payout mechanics, or establish extension amendments. It exclusively documents executive equity movement following the merger announcement. Investors tracking sponsor conduct and insider alignment relative to the April 20, 2028 deadline should note the zero-price disposal as a disclosed baseline for current insider concentration; however, the filing contains no forward-looking statements, customer or revenue claims, partnership details, litigation references, or revised strategic targets. Trust parameters and deal progression remain static per the issuer's own representations.
What changed: Form 4 – insider ownership report documenting a beneficial ownership change for JATT II Acquisition Corp. The filing states that JATT Ventures II L.P., identified by the registrant as a 10% owner, disposed of 225,000 shares at $0 on 2026-06-06, leaving the reporting entity with 1,800,000 shares afterward. The document does not reference the $10.07 trust/share value, the 2028-04-20 redemption deadline, any extension provisions, or the advancement of the announced acquisition. It contains no executive commentary, customer metrics, revenue data, market analyses, technological disclosures, partnership announcements, litigation details, or personnel updates. Why it matters: A reported reduction in sponsor-affiliated holdings can alter the actual equity split between founding and public shareholders prior to the 2028-04-20 conversion window, though the $0 execution price points to a non-market mechanism such as an internal assignment, settlement, or reorganization rather than a liquidation event. Because the Form 4 supplies no explanatory narrative beyond the share-count delta, the economic intent remains opaque to investors monitoring sponsor alignment and potential dilution mechanics ahead of the deal close. The filing leaves the stated trust balance, redemption calendar, and deal status unchanged.
What changed: Form 8-K filed as a Rule 425 communication announcing the execution of a definitive Business Combination Agreement between SPAC JATT II Acquisition Corp and Talawar Tx Inc., a preclinical-stage biotech company developing bispecific antibodies for immunology/inflammatory diseases. Includes the full BCA, Sponsor Support Agreement, Stockholder Support Agreement, PIPE Subscription Agreements, Registration Rights and Lock-Up Agreement, and an investor presentation. New definitive business combination: JATT will merge with Talawar (via Merger Sub), with each JATT share converting to one share of the combined company (PubCo). Talawar pre-money equity valuation: $120M. PIPE: $225M at $10/share (22.5M shares). Trust account: ~$60M (as of signing, per JATT representation). Minimum cash condition: Available Cash at closing must be at least $125M. Sponsor forfeits 150,000 JATT shares for no consideration. Sponsor and certain company stockholders enter into a 180-day lock-up. Post-closing board: up to 7 directors – 1 designated by sponsor (Dr. Someit Sidhu) and up to 6 by Talawar. Officers designated by Talawar. Outside Date: January 31, 2027 (extendable if financial statements delayed). Why it matters: This is the definitive deal that will determine the future of JATT. The trust value is $10.07/share; the PIPE is at $10.00, providing a floor. Combined cash (~$285M assuming no redemptions) is expected to fund Talawar's lead candidate TALA-125 through Phase 2b proof-of-concept data readout in 2H 2028. The PIPE is oversubscribed with top-tier healthcare investors. Redemption risk is mitigated by a $125M minimum cash condition. Sponsor forfeiture of 150k shares reduces dilution. The investor presentation provides detailed preclinical data and development timeline. This is a high-quality biotech acquisition with strong investor backing.
pipe, outside datenothing moved · 2 with no prior record of ours
- PIPE
- $30.0M · unchanged
- Outside date
- 2027-01-31 · unchanged
The clause …“(A) fundraising transactions from and after the date hereof (excluding the PIPE Financing) for aggregate net proceeds of up to $30,000,000 to the Company (the “ Company Interim Financing ”) and (B) grants and issuances of Company”…
The clause …“contemplated by this Agreement shall not have been consummated on or prior to January 31, 2027 (the “ Outside Date ”); provided that in the event that there shall have been a Financial Statement Delivery Failure by the Financial”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Form 425 filing containing a prescribed business combination announcement and a republished Fierce Biotech interview article featuring comments from Talawar Tx Inc. Chief Executive Officer Marc Schegerin. On June 29, 2026, JATT II Acquisition Corp. and Talawar Tx Inc. executed a Business Combination Agreement that will make JATT an indirect wholly-owned subsidiary of Talawar. According to CEO Marc Schegerin in the republished interview, Talawar announced an oversubscribed $225 million concurrent private investment in public equity led by Access Biotechnology, with participation from Bain Capital Life Sciences, Deep Track Capital, RA Capital Management, Janus Henderson Investors, Vianti Capital, and Farallon Capital Management. The parties state the combined company will receive $285 million total from JATT’s April IPO proceeds and the PIPE. JATT’s statutory business combination deadline remains April 20, 2028; the filing’s prospectus-style cautionary section reiterates the contractual risk that the transaction might not close by that date or that a sought extension could fail. No amendments to redemption procedures, trust accounting rules, sponsor equity warrants, or lock-up terms were disclosed in this communication. Why it matters: The PIPE term sheet and named anchor investors establish pre-vote institutional positioning ahead of the Form S-4 effectiveness, which triggers the formal registration/proxy sequence where JATT shareholders will be able to exercise redemption rights against the prevailing trust balance. The stated $285 million combined funding reservoir, paired with CEO Marc Schegerin’s clinical milestones (clinic entry in Q1 2027, interim phase 1 data by the end of 2027, and a phase 2b proof-of-concept readout penciled for H2 2028), outlines the milestone-driven burn schedule that will determine how much of the $10.07 per-share trust value survives closing versus being deployed to operations or dilutive financings. The filing’s explicit inclusion of SPAC-extinction and extension-failure risks reinforces standard termination protections without altering the redemption calendar or trust payout formula. Because the document primarily republishes a third-party interview rather than issuing original financial guidance, investors should treat all competitive landscape references (Sanofi, Regeneron, Eli Lilly, AbbVie), therapeutic mechanism claims, and strategic rationale as sourced commentary from the CEO and article author rather than audited corporate facts. For redemption trackers, this 425 communication finalizes the deal architecture and PIPE ledger, providing the necessary baseline to model trust preservation scenarios once the proxy statement is mailed and the extraordinary general meeting record date is set.
What changed: Form 8-K announcing a definitive business combination agreement between JATT II Acquisition Corp (SPAC) and Talawar Tx Inc. (target), including the merger agreement, sponsor support, PIPE financing, and related documents. JATT entered into a Business Combination Agreement with Talawar and Merger Sub on June 29, 2026. Key terms: (1) Each JATT share converts into one share of PubCo common stock; (2) A $225 million PIPE at $10.00 per share (22.5 million shares); (3) Sponsor (JATT Ventures II L.P.) agrees to vote in favor, waive redemption rights and anti-dilution, and forfeit 150,000 JATT shares for no consideration; (4) Minimum available cash condition of $125 million at closing; (5) Outside date for closing is January 31, 2027; (6) Combined company to be named Talawar Therapeutics and listed on Nasdaq under ticker ‘TLWR’; (7) Post-closing board: one sponsor director, up to six company directors; (8) Talawar’s lead program TALA-125 (anti-IL-13 x IL-18 bispecific for atopic dermatitis) expects CTA in YE 2026, Ph1 start 1Q27, Ph2b data 2H28; (9) Lock-up of 180 days for certain shares; (10) Registration rights filed within 30 days post-closing. Why it matters: This is the definitive agreement for the de-SPAC transaction. The trust per share is $10.07, but the PIPE price is $10.00, implying potential dilution. The $125 million minimum cash condition ensures sufficient operating capital. The valuation of Talawar at $120 million pre-money plus $225 million PIPE provides a pro forma equity value of ~$452 million. Sponsor share forfeiture reduces dilution. The lock-up restricts selling for 180 days. The investor presentation contains forward-looking clinical timelines and market projections for TALA-125. The transaction is subject to shareholder approval, SEC effectiveness, and Nasdaq listing.
pipe, outside datenothing moved · 2 with no prior record of ours
- PIPE
- not previously extracted$30.0M
- Outside date
- not previously extracted2027-01-31
The clause …“(A) fundraising transactions from and after the date hereof (excluding the PIPE Financing) for aggregate net proceeds of up to $30,000,000 to the Company (the Company Interim Financing ) and (B) grants and issuances of Company”…
SpacBrain reads this as the agreement may be terminated from 2027-01-31.
The clause …“contemplated by this Agreement shall not have been consummated on or prior to January 31, 2027 (the Outside Date ); provided that in the event that there shall have been a Financial Statement Delivery Failure by the Financial Statement”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: A Form 425 communication reproducing a LinkedIn post announcing the execution of a business combination agreement between JATT II Acquisition Corp and Talawar Tx Inc. No alterations to redemption deadlines, trust accounting, extension mechanisms, or sponsor behavior are disclosed. The filing confirms the June 29, 2026 agreement date and establishes the immediate regulatory pathway: both parties intend to file a Form S-4 registration statement containing preliminary and definitive proxy materials and a prospectus, culminating in a mailout to JATT shareholders for an extraordinary general meeting vote. Why it matters: Although mechanically inert, the filing provides the first substantive public characterization of the target's business and associated risk profile. Both JATT and Talawar Tx Inc. state they anticipate benefits derived from preclinical and clinical development plans, therapeutic advantages of product candidates, and market positioning. Conversely, both entities attribute significant execution uncertainties to these projections, specifically highlighting the early stages of clinical development, reliance on third-party suppliers and manufacturers, outcomes of future collaboration agreements, and the ability to obtain regulatory approval for successful commercialization. Investors tracking the April 2028 deadline should prepare for detailed deal economics and voting conditions in the upcoming S-4.
What changed: Quarterly report (10-Q) for the period ended March 31, 2026, filed before the SPAC's IPO closed on April 20, 2026. It covers the pre-IPO formation stage, including deferred offering costs, sponsor promissory note, and no operations. As of March 31, 2026, the SPAC had not yet completed its IPO: it had no cash, a working capital deficit of $204,792, and a promissory note from sponsor of $106,141. On April 20, 2026, subsequent to quarter end, the IPO closed with 6,000,000 units at $10.00, raising $60 million for the trust account (initially $10.00 per share). No business combination target has been selected or discussed. Why it matters: This filing establishes the baseline trust value ($10.00 per share) and confirms the 24-month deadline (April 20, 2028) for completing a business combination. It details sponsor commitments, including the working capital loan facility and founder shares subject to forfeiture. No deal has been announced, so this is foundational for tracking future redemptions, extensions, and sponsor conduct.
What changed: A Schedule 13G Joint Filing Agreement (Exhibit 99.1) executed under SEC Rule 13(d)(1)(k) by RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., establishing a consolidated reporting framework for their beneficial ownership of JATT II Acquisition Corp ordinary shares (par value $0.0001 per share). The filing introduces no alteration to beneficial ownership percentages, share quantities, redemption intentions, trust preservation, extension provisions, or the announced deal timeline ending April 20, 2028. Procedurally, the Filers authorize themselves to file a single Schedule 13G or 13D on behalf of all signatories, with any party permitted to dissolve the joint arrangement upon one week’s prior written notice or shorter mutual period. No mechanical adjustments to sponsor conduct, deal progress, or shareholder rights are documented or implied. Why it matters: While the Filers make no substantive assertions regarding customers, revenue, market size, strategy, technology, partnerships, or litigation, the procedural declaration carries forward-looking implications. The Filers create a compressed disclosure pathway that could streamline coordinated signaling—such as board nominations, tender intentions, or merger condition negotiations—should the group adjust its position ahead of the redemption window. Investors tracking institutional alignment should monitor whether this administrative wrapper transitions to a Schedule 13D or generates amended filings containing share counts or direct commentary, but absent those elements, the document remains a routine compliance instrument rather than a catalyst for valuation or deadline mechanics.
What changed: An SEC Schedule 13G beneficial ownership report. The provided excerpt names Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl as reporting parties. It contains no share counts, percentage thresholds, acquisition dates, purchase prices, or change-in-ownership metrics. There is no statement concerning redemption intentions, voting posture, trust account movements, deadline extensions, or business combination progression. Why it matters: This filing type functions as a statutory disclosure instrument for investors holding above regulatory ownership thresholds. In a SPAC framework, knowing which entities control equity positions helps investors model redemption liquidity, vote weight on a proposed merger, and sponsor alignment ahead of the scheduled deadline. Because the excerpt omits all numerical data, purpose-of-transaction declarations, and source-of-funds disclosures, it cannot currently quantify accumulation or distribution pressure, nor can it inform estimates regarding extension probability or trust preservation. The analytical impact remains unverified until the full schedule provides the omitted percentages and transactional history.(flagged for human review)
What changed: A Form 8-K Current Report filed by JATT II Acquisition Corp. disclosing the consummation of its Initial Public Offering, the establishment of a trust account, and the attachment of an audited balance sheet and comprehensive financial statement notes. As stated by the Company, on April 20, 2026 it consummated an IPO of 6,000,000 ordinary shares at $10.00 per share, generating $60,000,000 in gross proceeds. Simultaneously, the registrant completed a private placement sale of 300,000 Ordinary Shares to Sponsor JATT Ventures II L.P. for $3,000,000. The Company deposited $60,000,000 into a trust account held at Continental Stock Transfer & Trust Company. Financial notes state the Company will have 24 months from the April 20, 2026 closing to complete an initial business combination, establishing a definitive redemption/liquidation deadline near April 2028. The filing attributes insider equity allocations to the Sponsor and specific personnel: 1,725,000 founder shares to the Sponsor; 150,000 shares to Chief Executive Officer Dr. Someit Sidhu; 50,000 shares to Chief Financial Officer Mr. Nicholas Fernandez; 25,000 shares each to four independent directors; and 25,000 shares to an independent consultant. These 325,000 shares carry a recorded fair value of $800,800 ($2.46 per share) per a third-party valuation team using a 24.6% implied market adjustment on a $10.00 baseline. The Company also documents a $106,141 promissory note drawn from the Sponsor and a $20,000 per month administrative support agreement effective April 16, 2026. An underwriter over-allotment option for up to 900,000 additional shares at $10.00 per share remains unexercised. Why it matters: This filing confirms the mechanical foundation of the trust ($60,000,000 deposited for the benefit of 6,000,000 public shareholders, initially anticipated to be $10.00 per Public Share per the notes), locks in the 24-month execution window, and details the precise capital stack and incentive structures governing the acquisition search. The disclosed compensation mechanics—straight-line monthly vesting over 24 months or full acceleration upon a business combination—tie sponsor and management retention directly to successful deal completion. Working capital loans remain available to fund transaction costs, with up to $1,500,000 potentially convertible into private placement shares at $10.00 per share, introducing defined dilution parameters. Public shareholders retain standard redemption rights calculable as of two business days prior to consummation, while the sponsor and underwriter have contractually waived claims against the trust account in a liquidation scenario. Because the entity is a blank check company with zero operating revenues and no selected target, all investor evaluation rests on the published execution deadline, trust protections, and subsequent prospecting disclosures rather than historical financial performance.
What changed: Schedule 13G Joint Filing Agreement (Exhibit 1), dated April 24, 2026, filed on behalf of Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz. The provided text contains exclusively the joint filing agreement’s administrative language and signature pages. The signatories establish a procedural mechanism to file all future amendments collectively and each accepts responsibility solely for their own disclosed information, explicitly disclaiming liability for the others’ data. No share counts, percentage thresholds, transaction dates, or stated purposes for accumulation appear in this excerpt. Consequently, no modifications to the redemption timeline, trust distribution mechanics, extension provisions, or deal milestones are reported. Why it matters: For investors monitoring SPAC operations, this segment offers no actionable intelligence on redemption pressure, trust yield, sponsor governance, or merger advancement. The agreement confirms only that the listed holders have coordinated their Section 13(g) reporting channels, which reduces duplicate filings but does not alter voting power, dilution exposure, or liquidity conditions. The document makes zero assertions regarding customer concentration, revenue streams, addressable markets, strategic pivots, technological assets, commercial partnerships, pending litigation, or executive transitions. Until the accompanying Schedule 13G body items disclosing actual holdings are available, the filing remains a routine compliance exhibit with neutral implications for capital deployment timing.
What changed: Form 8-K filed by JATT II Acquisition Corp announcing the closing of its initial public offering of 6,000,000 ordinary shares at $10.00 per share, and the entry into related agreements (underwriting, trust, letter, registration rights, private placement, administrative services). The SPAC completed its IPO on April 20, 2026, raising $60,000,000 in gross proceeds. A total of $60,000,000 was deposited into a trust account (Continental Stock Transfer & Trust Company). The sponsor purchased 300,000 private placement shares for $3,000,000. The board of directors was appointed and committees formed. The amended and restated memorandum and articles were filed. The trust will be held until the earliest of a business combination, liquidation if no deal within 24 months (by April 20, 2028), or certain charter amendments. Why it matters: This filing establishes the initial trust value of $60,000,000 ($10.00 per public share), the 24-month deadline for a business combination (April 20, 2028), and the terms governing sponsor shares, lock-ups, and redemption rights. It provides the baseline for tracking future redemptions, extensions, and deal progress.
What changed: SEC Form 4 — Insider Ownership and Trading Report. The filing documents an open-market purchase by Sidhu Someit, who holds the titles of director and chief executive officer and is identified as a 10% owner, of 300,000 shares on 2026-04-20, resulting in a post-transaction holding of 2,025,000 shares. Regarding the specified mechanics—redemption deadlines, trust value, extensions, deal progress, and sponsor conduct—the Form 4 discloses none. It does not alter the business combination timeline, address trust accounting, propose an extension, detail merger negotiations, or outline sponsor compensation or governance changes. Why it matters: This Form 4 reflects routine post-acquisition trading disclosure rather than a corporate action affecting shareholder economics. Because it contains no proposals to amend the business combination timeline, adjust trust accounting, trigger redemption gates, or announce target selection, it does not independently shift the calendar or valuation parameters. Investors monitoring JATT should treat this as a baseline reporting update and watch for subsequent proxy statements, merger agreements, or S-4 amendments that would directly govern redemption rights, trust payouts, extension voting, or deal execution.
What changed: A Form 4 insider ownership report documenting a securities transaction by a principal stockholder. Per the filing, on 2026-04-20 the reporting person JATT Ventures II L.P. (identified as a 10% owner) completed an open-market purchase acquiring 300,000 shares, leaving it with 2,025,000 after. The document reports no adjustments to the redemption deadline, trust valuation, extension timeline, or deal progress; it solely records the share acquisition. Why it matters: The transaction signals sponsor conduct and outside-trust capital deployment, which investors tracking the DEAL_ANNOUNCED phase should monitor for alignment with public shareholders. Increasing the 10% owner’s stake to 2,025,000 after may influence voting weight and secondary market supply ahead of the upcoming corporate action window, though the filing discloses no new contractual terms or operational metrics.
What changed: Prospectus for an initial public offering (IPO) of a special purpose acquisition company (SPAC), filed pursuant to Rule 424(b)(4). The company is a blank check company seeking a business combination, with no target selected. Initial public offering of 6,000,000 ordinary shares at $10.00 per share, with an over-allotment option for up to 900,000 additional shares. Proceeds of $60 million ($69 million if over-allotment exercised) will be deposited in a trust account. The SPAC has 24 months from closing (expected April 20, 2026) to complete a business combination. No warrants are issued. Public shareholders may redeem shares upon a business combination or if no deal is completed by the deadline. A 20% per-shareholder redemption limit applies. Sponsor purchased 1,725,000 founder shares at approximately $0.014 per share and will purchase 300,000 private placement shares at $10.00 per share. AI Biotechnology, an affiliate of Access Industries, has indicated a non-binding interest to purchase up to $30 million of ordinary shares in a PIPE concurrent with a business combination. Why it matters: This filing establishes the full terms of the SPAC IPO, including trust per-share value ($10.00), redemption mechanics, deadline (April 2028), sponsor economics, and potential conflicts of interest. It is the baseline for all future redemptions, extensions, and deal progress. The indication of interest from AI Biotechnology for a potential $30 million PIPE is a notable feature that may affect deal financing and dilution.
What changed: A routine compliance exhibit: a Form 3 initial statement of beneficial ownership reporting Director Arjun Goyal’s indirect holding of 25,000 shares in JATT II Acquisition Corp. Per the filing, there are no revisions to redemption schedules, trust per-share valuations, extension options, target acquisition progress, or sponsor conduct. The document solely records the initial disclosure of 25,000 indirectly held shares by Director Arjun Goyal. Why it matters: This standard regulatory submission establishes baseline director equity alignment immediately following the announced deal phase. Attributed to the Form 3 filing, the 25,000-share position confirms leadership capital remains exposed without shifting redemption pressures, trust account operations, or sponsorship obligations. No financing contingencies, shareholder votes, or acquisition timelines are altered, meaning the exhibit functions purely as an ownership ledger update with zero mechanical impact on the public market or trust lifecycle.
What changed: SEC Form 3 (initial statement of beneficial ownership) reporting indirect insider equity positions. Director Christopher Staral disclosed a current indirect holding of 25,000 shares as of the 2026-04-17 filing date. The report notes no purchase, sale, or conversion of securities; it merely establishes the baseline of 25,000 shares. This filing does not alter the already announced merger timeline, the April 20, 2028 redemption deadline, or the documented $10.07 trust/share balance. Why it matters: Tracking director holdings provides a reference point for sponsor alignment and potential lock-up or voting behavior ahead of the combination close, though the 25,000 share count does not intersect with public redemption mechanics or trust distribution schedules. Attributed solely to the regulatory submission by Staral, Christopher (director), the exhibit contains no additional claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or corporate personnel.
What changed: A routine compliance exhibit classified internally as a FORM 3 insider ownership report. Per the filing, JATT Ventures II L.P., designated as a 10% owner, maintains a direct holding of 1,725,000 shares in JATT II Acquisition Corp. The document makes no reference to redemption calendars, trust valuations, extension provisions, merger target selection, business combination progress, or sponsor conduct modifications. Why it matters: For investors monitoring redemption windows, trust distributions, extension votes, or deal progression, this administrative disclosure does not shift mechanical parameters or alter investor decision timelines. According to the filing, the only substantive fact recorded is a static snapshot of a single reporting person’s direct equity position totaling 1,725,000 shares at a 10% ownership designation. Because the document contains zero claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel, it offers no forward-looking catalysts or risk factors beyond baseline insider concentration. Routine Form 3 submissions of this nature are standard regulatory record-keeping and do not independently trigger tendering considerations or liquidation scheduling without accompanying Forms 4 or 5 filings, special meeting notices, or definitive agreements.
What changed: A routine compliance exhibit/Form 8-A filing for the registration of certain classes of securities pursuant to Section 12(b) of the Securities Exchange Act of 1934. According to the document executed by Chairman and Chief Executive Officer Someit Sidhu on April 16, 2026, JATT II Acquisition Corp formally registers its ordinary shares (par value $0.0001 per share) for listing on The Nasdaq Stock Market LLC. The filing incorporates by reference the security description from the Registration Statement on Form S-1 (File No. 333-294294, originally filed March 13, 2026). It explicitly notes that no exhibits are required because no other securities are registered on Nasdaq and the registration is not under Section 12(g). The filing does not modify redemption calendars, trust account structures, extension procedures, merger execution timelines, or sponsor conduct rules; those parameters remain sourced to the previously filed S-1. Why it matters: Beyond exchange qualification and incorporations by reference, the filing contains no substantive claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel. As a procedural listing confirmation, it finalizes a regulatory exchange step required post-deal announcement, ensuring the ordinary shares meet Nasdaq’s qualification standards for quotation and settlement. For investors, it verifies the sponsor’s vehicle has satisfied a mandatory compliance milestone without altering any economic terms, pricing benchmarks, or shareholder voting thresholds.
What changed: A Form 3 filing, identified in its own terms as an insider ownership report documenting the initial acquisition of beneficial ownership of equity securities. The filing discloses that JATT II Acquisition Corp. director Kluft Jonathon holds 25,000 shares indirectly as of the reported date of 2026-04-16. No amendment is made to the SPAC’s deal status, redemption deadline, trust accounting, or extension framework; those mechanics remain untouched by this submission. Why it matters: This is a routine regulatory compliance exhibit filed to satisfy early-insider reporting obligations under Section 16(a) of the Exchange Act. It contains no claims about customers, revenue, market size, strategy, technology, partnerships, litigation, or sponsor conduct. The only quantitative data point—the director’s indirect holding of 25,000 shares—is self-attributed by Kluft Jonathon and carries no weight on public shareholder redemption calculations, trust liquidation triggers, or sponsor behavioral assessments beyond confirming baseline insider position tracking.
What changed: SEC Form 3—Insider Ownership Report. This document is an SEC Form 3—routine compliance exhibit recording insider beneficial ownership. Bearing on SPAC mechanics, it discloses no modification to the 2028-04-20 redemption deadline, the $10.07 trust value per your parameters, or the DEAL_ANNOUNCED status. Director Verender S. Badial is reported as holding 25,000 shares indirectly. Regarding further substance, the filing contains no statements regarding customers, revenue, market size, acquisition strategy, technology, partnerships, pending litigation, or personnel changes; it solely documents the director’s indirect share count per the Form 3 text. Why it matters: For investors tracking redemption windows, trust accounting, sponsor behavior, and deal execution, this filing confirms routine fiduciary disclosure without altering trust mechanics, conversion rights, or the April 20, 2028 expiration. Because the exhibit lacks transaction pricing, source-of-funds details, or business combination milestones, it provides no immediate signal regarding sponsorship commitment, anticipated redemption pressure, or trust distribution timelines. All referenced metrics derive exclusively from the submitted Form 3 and your provided filing metadata.
What changed: A Form 3 initial statement of beneficial ownership of securities, functioning as a routine compliance exhibit required under Section 16(a) of the Securities Exchange Act of 1934. The filing records that Nicholas Fernandez, Director and Chief Financial Officer of JATT II Acquisition Corp., beneficially holds 50,000 indirect shares as of the 2026-04-16 reporting date. This entry updates the public ledger of executive equity positions but introduces no amendments to the proposed business combination, shareholder redemption parameters, trust account valuation methodology, or extension triggers. The provided $10.07 per-share trust balance and the 2028-04-20 consummation deadline remain unadjusted by this submission. Why it matters: For investors tracking redemption calendars, sponsor conduct, and deal mechanics, this disclosure establishes a baseline measure of inside economic alignment at the time of filing. Fernandez’s self-reported 50,000 indirectly held shares confirm personal capital exposure to the listed vehicle, yet the document contains no forward-looking assertions regarding customer contracts, revenue forecasts, total addressable market sizing, proprietary technology disclosures, strategic partnerships, or active litigation. Consequently, the filing does not alter the investor exit calculus, nor does it signal any shift in sponsor commitment or transaction pacing. Attribution: JATT II Acquisition Corp.’s SEC submission filed 2026-04-16, disclosing the holding reported by Fernandez.
What changed: a Form 3 — insider ownership report. The filing states that Sidhu Someit, identified as a director and Chief Executive Officer, holds 1,725,000 shares indirectly. Nothing in the submission alters the redemption deadline of 2028-04-20, the reported trust value per share of $10.07, pending business combination status, extension provisions, or shareholder redemption mechanics. Why it matters: For investors tracking sponsor conduct and deal progress, the document confirms the CEO’s indirect equity position as a static compliance snapshot, without accompanying buy/sell transactions, lock-up terms, or vesting conditions tied to transaction closing. Because the filing reports a fixed holding rather than a capital-altering event, it carries no mechanical impact on the April 2028 termination clock, public share counts, or trust account distribution schedules. All ownership figures and titles are attributed directly to Mr. Someit’s self-reporting; the text contains no external claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel.
What changed: A corporate letter to the SEC Division of Corporation Finance requesting acceleration of the effective date of Registration Statement No. 333-294294 under Rule 461 of the Securities Act of 1933. Nothing regarding the mechanics of redemption, trust value, extensions, deal progress, or sponsor conduct has changed. The filing simply asks the Commission staff to declare the referenced registration statement effective on April 16, 2026, at 4:00 p.m. Eastern Time, acknowledging the Company’s ongoing obligations under the Act. Why it matters: The correspondence signals routine regulatory processing toward bringing a previously filed transaction document into operative effect, indicating Company management intends to finalize SEC clearance by mid-April 2026. It contains no substantive disclosures regarding a target company, customer base, revenue, market size, strategy, technology, partnerships, litigation, or personnel updates. Chief Executive Officer Someit Sidhu signed the request, confirming continued executive oversight. As this is a pure procedural timing submission, it alters no previously established redemption windows, trust account balances, extension rights, or deal terms.
What changed: This document is a Rule 461 correspondence submitted by underwriter representative Guggenheim Securities, LLC, requesting the SEC to accelerate the effective date of JATT II Acquisition Corp’s Form S-1 Registration Statement (File No. 333-294294) to April 16, 2026 at 4:00 p.m., Washington D.C. time. Mechanically, the filing advances the IPO registration timeline by seeking early SEC approval. Guggenheim Securities, LLC states it has distributed preliminary prospectus copies dated April 2, 2026 and certifies ongoing compliance with Rules 460 and 15c2-8. The submission does not modify any previously disclosed April 20, 2028 business combination deadline, does not alter the reported trust value, does not trigger or define shareholder redemption windows, does not propose trust account extensions, and provides no updates on sponsor conduct or merger execution beyond confirming underwriting distribution protocols. The correspondence is signed by Michael Jiang, Senior Managing Director at Guggenheim Securities, LLC. Why it matters: Substantively, accelerating the S-1 effective date to April 16, 2026 is the procedural gateway to pricing the public offering and funding the trust account. Until the IPO formally closes, no public shares exist to be redeemed, meaning this filing merely establishes the calendar foundation for all subsequent redemption valuations and liquidation triggers. No additional claims regarding customer contracts, revenue, market sizing, technology, partnerships, litigation, or executive transitions appear in the text.
What changed: A correspondence letter addressed to the U.S. Securities and Exchange Commission’s Division of Corporation Finance withdrawing a prior request to accelerate the effective date of JATT II Acquisition Corp’s Form S-1 registration statement (File No. 333-294294). Guggenheim Securities, LLC, identified as the Representative for the underwriters, and JATT II Acquisition Corp jointly submitted this filing via EDGAR on April 6, 2026 to rescind their earlier request made on April 3, 2026. That earlier request sought to declare the registration statement effective at 4:00 p.m. Eastern Time on April 6, 2026 under Rule 461. By withdrawing the acceleration request, the Company and the Representative have paused the regulatory effective-date mechanism for the public offering. The letter discloses no adjustments to trust accounting, shareholder redemption rights, business combination deadlines, or sponsor commitments. Why it matters: The withdrawal halts the immediate pricing and settlement timeline for the referenced offering, preserving the current capital structure while presumably addressing SEC staff comments or internal alignment. Because the Company and the Representative made no statements regarding an announced merger, target valuation, or operational metrics, the filing does not advance the investor’s view of deal execution risk or asset quality. The filing contains no claims about customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel. Confidence reflects high certainty in the mechanical reading of the correspondence, though forward-looking implications depend on subsequent filings.
What changed: A routine compliance correspondence to the SEC Division of Corporation Finance formally withdrawing a previously submitted request to accelerate the effective date of the Company’s Form S-1 registration statement. The Company withdrew its April 3, 2026 request to have the Registration Statement declared effective on Monday, April 6, 2026, at 4:00 p.m. Eastern Time. No adjustments to the business combination deadline of April 20, 2028, the per-share trust balance of $10.07, shareholder redemption mechanics, or extension parameters are reported or altered by this filing. Why it matters: The withdrawal temporarily defers the accelerated effective date of the registration, which typically signals a pause while the issuer awaits further SEC feedback or resolves disclosure items; it does not advance or delay the tracked redemption calendar or trust value. The document contains no substantive claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel beyond identifying Chief Executive Officer Someit Sidhu as the signatory under Registration File No. 333-294294.
What changed: A Rule 461 correspondence requesting SEC acceleration of the effective date for JATT II Acquisition Corp’s Form S-1 registration statement. Guggenheim Securities, LLC confirms it distributed the preliminary prospectus dated April 2, 2026 to participating underwriters and dealers, and formally requests the SEC declare the registration statement effective on April 6, 2026 at 4:00 p.m. Washington D.C. time. The filing makes no reference to, nor alters, any redemption mechanics, trust valuation methods, extension provisions, or target acquisition status. Why it matters: Accelerated effective dates directly control when public securities become freely tradable, when IPO proceeds settle into the trust account, and how the statutory business combination timeline begins running. Because this submission is purely administrative, it leaves all underlying structural guardrails for redemptions, sponsor overhang, and extension options intact. All assertions regarding prospectus circulation and quotation rule compliance were originated by Guggenheim Securities, LLC, under the authority of Senior Managing Director Michael Jiang. The document contains zero substantive claims concerning customer pipelines, revenue metrics, addressable market size, proprietary technology, strategic partnerships, litigation posture, or sponsor governance conduct.
What changed: This document is a Securities and Exchange Commission correspondence (CORRESP) from JATT II Acquisition Corp, authored and signed by Chief Executive Officer Someit Sidhu, formally requesting acceleration of the effective date for Registration Statement No. 333-294294 pursuant to Rule 461 under the Securities Act of 1933. The filing asks the Commission to declare the Registration Statement effective on April 6, 2026 at 4:00 p.m., Eastern Time, or as soon as practicable thereafter. Regarding redemption deadlines, trust valuations, extensions, deal progress, and sponsor conduct, the letter does not alter external parameters but advances deal progress by moving a regulatory checkpoint forward. Chief Executive Officer Someit Sidhu represents that the Company acknowledges its statutory obligations and routes the request through the Office of Real Estate & Construction to Pamela Howell. The document contains no substantive claims regarding customers, revenue, market size, strategic direction, proprietary technology, commercial partnerships, active litigation, or executive transitions. Why it matters: Compressing the interval between SEC comment resolution and regulatory effectiveness dictates the sequencing of shareholder notices, which governs when redemption rights formally attach and how quickly transaction proceeds may be deployed. Management’s acceleration bid signals a preference for uninterrupted execution over procedural delay, implying continued sponsor alignment with the originally outlined business combination roadmap. Because the submission functions strictly as a timing mechanism under Section 461, it carries no independent financial or operational disclosures; investors must await subsequent proxy statements or merger agreements to verify concrete deal terms, valuation benchmarks, or contingent consideration structures.
What changed: Amendment No. 1 to Form S-1 Registration Statement for a new SPAC initial public offering (IPO), filed by JATT II Acquisition Corp. to register its ordinary shares for public sale. This is an amendment (the first) to the registration statement. The filing updates and completes the preliminary prospectus with current information, including revised dilution tables, updated financial data (balance sheet as of February 13, 2026), detailed descriptions of the offering's structure, sponsor compensation, trust mechanics, redemption rights, extension provisions, risk factors and conflicts of interest. Why it matters: This document provides the complete terms for JATT II's $60 million SPAC IPO. It confirms: a 24-month deadline from closing to complete a business combination (no automatic monthly extension); a $10.00 trust per share (with $0.30 deferred underwriting); a 20% per-shareholder cap on redemptions in a vote scenario; a commitment from sponsor to purchase 300k private placement shares at $10.00; and an indication of interest from AI Biotechnology (an Access Industries affiliate) for up to $30 million in a concurrent private placement at the time of the business combination. The filing also provides extensive biographical information on CEO Dr. Someit Sidhu (former JATT I / Zura Bio CEO) and the rest of the life-sciences-focused management team and board, outlining the sponsor's compensation and conflicts of interest.
What changed: SEC Division of Corporation Finance correspondence advising that the staff has not reviewed and will not review the company’s Registration Statement on Form S-1. No information in this filing alters the SPAC’s stated redemption deadline of 2028-04-20, trust value of $10.07 per share, extension mechanics, target deal progress, or sponsor conduct. The SEC simply declined to review the S-1. Why it matters: The letter, issued by the Division of Corporation Finance’s Office of Real Estate & Construction, states the SEC will neither review nor comment on the S-1 filed March 13, 2026. It reminds Chief Executive Officer Someit Sidhu and company management that they remain solely responsible for the accuracy and adequacy of their disclosures, notwithstanding the staff’s absence of action. The division cites Rules 460 and 461 regarding acceleration requests and directs inquiries to Pam Howell at 202-551-3357. The document contains no substantive claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or financial metrics. All referenced data points—including the filing date March 24, 2026, the S-1 submission date March 13, 2026, File No. 333-294294, the phone number 202-551-3357, and the address components 153 Central Avenue, C/O 56, and 07091—appear exactly as printed in the text.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.